Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy

Multiple Myeloma (MM)

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

Blood Cancer J

Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TAW, Fenk R, Müller F, Tovar N, Oliver-Cáldes A, Rathje K, Davis JA, Fandrei D, Vucinic V, Kharboutli S, Baermann BN, Ayuk F, Platzbecker U, Albici AM, Schub N, Schmitz F, Shune L, Khouri J, Anwer F, Raza S, McGuirk J, Mahmoudjafari Z, Green K, Khandanpour C, Teichert M, Jeker B, Hoffmann M, Kröger N, von Tresckow B, de Larrea CF, Pabst T, Abdallah AO, Gagelmann N

doi: 10.1038/s41408-024-01197-2

Multiple Myeloma (MM)

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Blood

Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C, von Tresckow B, Wulf GG, Weisel KC, Blau I, Engelhardt M, Wäsch R, Schub N, Teipel R, Hecker JS, Waldschmidt JM, Besemer B, Baermann BN, Call S, Hansmann L, Ayuk FA, Raab MS, Einsele H, Platzbecker U, Kröger N

doi: 10.1182/blood.2025028330

Multiple Myeloma (MM)

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma

Blood Cancer J

Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Morán-Segura CM, Nguyen JV, Lekakis L, Fernandez-Pol S, Samraj AN, Naresh KN, Vazquez-Martinez M, Baz RC, Spiegel JY, Mikkilineni L, Gubatan JM, Sidana S, de Menezes Silva Corraes A, Kalariya NM, Patel KK, Shim KG, Fonseca R, Ferreri C, Voorhees PM, Richard S, Valdes CR, Sireesha Asoori, Wolf JL, Cowan AJ, Sborov DW, Locke FL, Lin Y, Wang Y, Hansen DK

doi: 10.1038/s41408-024-01167-8

Multiple Myeloma (MM)

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma

N Engl J Med

Harrison SJ, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, Rahman M, Le Bris Y, Er J, Eugene-Lamer J, Haynes NM, Li J, Abbott RC, Bodet-Milin C, Moreau A, Letouzé E, Lendvai N, Schecter JM, Deraedt W, Banerjee A, Lengil T, Vogel M, Foulk B, Zhao H, Smirnov D, Slaughter A, Lonardi C, Lee E, Marquez L, Sankari A, Plaks V, Filho JOC, Patel N, Geng D, Gastinne T, Kelly H, Tiong IS, Eveillard M, Chevallier P, Lade S, Moreau P, Grimmond S, Oliaro J, Tessoulin B, Blombery P

doi: 10.1056/NEJMoa2309728

EHA/ICML 2025

Lymphoma

Expanding the Curative Potential of CAR T-Cell Therapy

Further Publications

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

Clin Cancer Res

Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA, Cordas Dos Santos DM, Rejeski K

doi: 10.1158/1078-0432.CCR-24-1798

Lymphoma

Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies

Leuk Lymphoma

Grunblatt E, Meng Z, Baldridge AS, Patel NP, Stanisic A, Feinstein MJ, Rao A, Gordon LI, Winter JN, Ma S, Mehta J, Singhal S, Karmali R, Akhter N

doi: 10.1080/10428194.2024.2448713

Lymphoma

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Blood

Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Beyar-Katz O, Bücklein VL, Curran KJ, Einarsdottir S, Esensten JH, Glaubach N Dr, Golan-Accav N, Gomez-Llobell M, Halamis I, Itzhaki O, Locke FL, Mailankody S, Marcus R, Maus MV, Palomba ML, Park JH, Pasquini MC, Raj SS, Rajeeve S, Salles GA, Scordo M, Shah GL, Shimoni A, Subklewe M, Tix T, Usmani SZ, Valid OB, Valtis YK, Zuckerman T, Shah NN, Perales MA, Shouval R

doi: 10.1182/blood.2025028833

Lymphoma

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell Lymphoma

Clin Cancer Res

Jhaveri K, Thapa R, Ercan D, Saha A, Noble J, Singh P, Fahrmann J, Saini N, Wu R, Dennison JB, Hanash S, Jenq RR, Modi K, Figura N, Chavez J, Shah B, Nishihori T, Lazaryan A, Khimani F, Bachmeier C, Gage K, Mishra A, Perna F, Davila ML, Spiegel J, Rejeski K, Subklewe M, Locke FL, Freeman C, Parker N, Jain MD

doi: 10.1158/1078-0432.CCR-24-3782

Related content

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma

Expanding the Curative Potential of CAR T-Cell Therapy

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell Lymphoma